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Abstract 19 
Neutrophils, monocytes and the endothelium are critical to ANCA-associated vasculitis (AAV) 20 
pathogenesis. This study aimed to develop a 4-dimensional (4D) live-cell imaging system that 21 
would enable investigation of spatial and temporal dynamics of these cells in health and 22 
disease. We further aimed to validate this system using autologous donor serum from AAV 23 
patients and polyclonal ANCA IgG, as well as exploring its potential in the pre-clinical testing 24 
of putative therapeutic compounds. Neutrophils and monocytes were isolated from peripheral 25 
venous blood of AAV patients or healthy controls and co-incubated on an endothelial 26 
monolayer in the presence of autologous serum. Alternatively, polyclonal ANCA IgG was 27 
used, following TNF-α priming, and imaged in 4-dimensions for 3 hours using a spinning disc 28 
confocal microscope. Volocity 6.3® analysis software was used for quantification of leukocyte 29 
dynamics. The use of autologous serum resulted in increased neutrophil degranulation (P = 30 
0.002), transmigration (P = 0.0096) and monocyte transcellular transmigration (P = 0.0013) in 31 
AAV patients. Polyclonal MPO-ANCA IgG induced neutrophil degranulation (P < 0.001) in 32 
this system. C5aR1 antagonism reduced neutrophil degranulation (P < 0.0002). We have 33 
developed a novel 4D in vitro system that allows accurate quantification of multiple neutrophil- 34 
and monocyte-endothelial interactions in AAV in a single assay. This system has the potential 35 
to highlight dynamics key to pathophysiology of disease, as well investigating the impact of 36 
potential therapeutics on these functions. 37 
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1. Introduction 44 
Anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) is a group of 45 
devastating autoimmune disorders characterised by relapsing necrotising vasculitis of small 46 
blood vessels, commonly involving kidneys and lungs. Considering the aggressive 47 
inflammation and multisystem nature of AAV, it is associated with significant morbidity and 48 
mortality [1]. The aetiology of AAV is unclear, but genetic and environmental factors, 49 
including infections, are proposed in the initiation of autoimmunity through dysfunctional 50 
innate and adaptive immune responses [2]. ANCA autoantibodies develop in susceptible 51 
individuals and target the antigens myeloperoxidase (MPO) and proteinase 3 (PR3). These 52 
antigens are present in the azurophilic granules of neutrophils and lysosomes of monocytes [3].  53 
ANCA activate neutrophils and monocytes in vitro and contribute to the pathogenesis of AAV 54 
through inappropriate activation of several innate immune mechanisms including 55 
degranulation, cytokine production and generation of reactive oxygen species [4,5]. In vivo 56 
studies have further supported a role for ANCA in AAV pathogenesis [6–8]. Passive transfer 57 
of MPO-ANCA into recombinase-activating gene-2-deficient mice resulted in the development 58 
of features of AAV including pauci-immune glomerulonephritis, granulomatous inflammation 59 
and haemorrhagic pulmonary capillaritis [6]. Persistent inflammation in AAV causes 60 
upregulation of adhesion molecules on leukocyte and endothelial cell surfaces, facilitating the 61 
migration and transmigration of leukocytes into neighbouring tissue. Leukocyte degranulation 62 
then occurs and damages the endothelium due to release of toxic enzymes and this cycle 63 
continues, resulting in end organ damage [9–11]. This process is further driven in response to 64 
chemotactic factors, such as complement component 5a (C5a), which has been shown to have 65 
a prominent role in AAV pathophysiology [12,13]. In addition, recent clinical trial data showed 66 
that C5a receptor inhibition was effective in replacing high dose glucocorticoids in AAV [14]. 67 
Traditionally in vitro studies have focused on single cell populations [4,15,16], particularly 68 
neutrophils, and often restricted to study limited number of readouts. This prevents individual 69 
cellular influences to be quantified accurately. Sophisticated in vitro studies are invaluable in 70 
examining the contribution of interactions between leukocytes and endothelium, or other cells 71 
e.g. platelets, towards disease initiation and progression. In this study, we aimed to develop a 72 
4D system that would allow investigation of these spatial and temporal dynamics of monocyte- 73 
and neutrophil-endothelial interactions in leukocytes isolated from patients with AAV. This, 74 
for the first time, would allow multiple features of AAV pathophysiology to be examined in a 75 
co-culture assay. We then aimed to validate this system using autologous patient serum, or 76 
polyclonal ANCA IgG, to highlight potential pathophysiologic differences. We hypothesise 77 
that ANCA IgG will show increased degranulation and transmigration in neutrophils and 78 
monocytes compared to anti-GBM and control IgG. Finally, we investigate the impact of C5aR 79 
antagonism on key leukocyte dynamics as an example of how this system could be employed 80 
to test therapeutic compounds. 81 
  82 
2. Materials and Methods 83 
2.1 Patients and Samples 84 
This study was conducted in accordance with the recommendations for physicians involved in 85 
research on human subjects adopted by the 18th World Medical Assembly, Helsinki 1964 and 86 
later revisions under the ethical approval of the North of Scotland Research Ethics Committee 87 
REC reference 13/NS/0028. AAV patients were identified via the Vasculitis Clinic at Aberdeen 88 
Royal Infirmary. Following informed consent, peripheral venous blood was collected from 25 89 
AAV patients with a diagnosis of either Granulomatosis with Polyangiitis (GPA), Microscopic 90 
Polyangiitis (MPA) or Eosinophilic Granulomatosis with Polyangiitis (EGPA) according to 91 
Chapel Hill consensus definitions [17] and 16 healthy donors for investigation of autologous 92 
serum and leukocytes. To investigate the role of complement C5aR1, 6 active AAV patients 93 
were recruited (supplementary material Table 1). Polyclonal ANCA IgG experiments utilised 94 
only healthy donor cells (n = 12). Vasculitis activity was measured using Birmingham 95 
Vasculitis Activity Score (version 3) [18] and clinical data was obtained for all patients, 96 
including AAV diagnosis, disease duration, ANCA status, organ involvement, C-reactive 97 
protein levels, estimated glomerular filtration rate, creatinine levels and treatments. 98 
2.2 Leukocyte Preparation 99 
Immediately following collection of blood, fresh peripheral blood mononuclear cells (PBMCs) 100 
were isolated by density centrifugation on LymphoprepTM (Axis-Shield, Norway), followed by 101 
positive selection of CD14+ monocytes using the MACS system (Miltenyi Biotec, Germany), 102 
according to manufacturer’s instructions. 103 
Neutrophils were isolated by density centrifugation using Histopaque 1119/1077 (both Sigma, 104 
Dorset, United Kingdom).   105 
Leukocytes were fluorescently labelled with carbocyanine dyes 1,1'-Dioctadecyl-106 
3,3,3',3'tetramethylindodicarbocyanine 4-chlorobenzenesulfonate (DiD) or Vybrant 107 
3,3′dihexadecyloxacarbocyanine perchlorate (DiO) (2.5µl) (Molecular Probes, Invitrogen, 108 
Massachusetts, United States), re-suspended at a density of 1.5 x 106 each in CO2-independent 109 
medium containing either 10% volume/volume autologous serum alone or plus 25 nM selective 110 
C5aR1 inhibitor, NDT 9513727 (Tocris Bioscience, Abingdon, United Kingdom) vs control 111 
dimethyl sulfoxide (DMSO). For polyclonal ANCA IgG experiments, leukocytes were isolated 112 
from healthy controls (HCs) and stained as above, primed with 2ng/ml TNF-α for 20 min at 113 
37°C. Primed leukocytes were incubated with 200 µg/ml, plasma protein G purified, PR3-114 
ANCA or MPO-ANCA to represent AAV disease or control IgG which included anti-GBM, 115 
ANCA-negative, transplant patients and healthy donors, throughout the 3 hour imaging assay. 116 
The polyclonal IgG identity was blinded until post analysis. 5μg/ml monoclonal MPO-ANCA 117 
(Clone 2C7, Origene) was incubated with TNF-α primed neutrophils to induce degranulation 118 
and supernatant collected to quantify lactoferrin by sandwich ELISA (Abcam, UK) 119 
(supplemental data Figure 2) to confirm visualisation of degranulation in the in vitro system.  120 
2.3 Endothelial Cell Culture 121 
Adherent HUVEC-C cell line C (American Type Culture Collection (ATCC), Manassas, 122 
Virginia, USA) were seeded into ‘µ-slide 2 well glass bottom dish’ (Ibidi, Munich, Germany) 123 
> 24 hours prior to imaging to form a confluent monolayer.  HUVEC-C were labelled with 124 
5µM CellTrace Violet (Molecular Probes, Invitrogen, Massachusetts, United States) before 125 
imaging with neutrophils and monocytes in the presence of CO2-independent medium 126 
containing 10% volume/volume autologous donor serum, 200 U/ml penicillin-streptomycin 127 
antibiotics and 2 mM L-glutamine (Invitrogen, Paisley, United Kingdom). 128 
 129 
2.4 Image Processing and Data Collection 130 
Neutrophils, monocytes and HUVEC were then immediately imaged following labelling using 131 
an Ultra Vox spinning disc confocal with a Yokogawa® CSU-X1 and additional micro lens 132 
spinning disc in the co-culture with HUVEC-C for 3 hours. Volocity 6.3 (Perkin Elmer, 133 
Massachusetts, United States) imaging analysis software was used to quantify the leukocyte 134 
functions including degranulation, migration and transmigration. Distinction between 135 
paracellular or transcellular routes of transmigration can also be quantified (supplemental data 136 
Figure 1). 137 
2.5 Statistical Analysis 138 
Statistical analysis was performed using Graphpad Prism software version 7 (Graphpad 139 
Software Inc, La Jolla, CA, USA). All data was tested for Gaussian distribution using the 140 
D’Agostino and Pearson normality test. Patient versus healthy population data was tested for 141 
significance using unpaired t-test (parametric) or Mann-Whitney test (non-parametric). 142 
Comparison of more than 2 data sets were analysed for using a One-way ANOVA. Actual 143 
statistical tests used will be stated throughout. 144 
  145 
3. Results 146 
3.1 Development of 4-Dimensional Imaging System 147 
In order to investigate leukocyte-endothelial dynamics in 4D we developed a system that allows 148 
quantification of leukocyte-endothelial dynamics relevant to the pathophysiology of AAV. 149 
This required fluorescent labelling of leukocyte and endothelial cell membranes with 150 
fluorophores that were bright at low concentrations, low photo-toxicity, non-transferrable and 151 
quick staining protocols in order to minimise handling of cells (as detailed in Section 2).  152 
Use of sophisticated image analysis software, Volocity 6.3, in combination with advanced 153 
microscopy technique, allowed combined and/or independent visualisation and quantification 154 
of leukocyte-endothelial cell dynamics.  For example, this system can be visualised as a whole 155 
4D image (Figure 1A; supplementary material Movie 1), or specific functions can be focused 156 
on. Leukocyte degranulation (Figure 1B/1D; Movie 2 and 3) can be quantified visually. We 157 
stimulated with monoclonal MPO-ANCA, a potent inducer of degranulation, and then 158 
correlated with lactoferrin, a traditional biochemical marker of degranulation, to confirm that 159 
this system accurately represented this dynamic (supplemental data Figure 2). The system can 160 
also investigate adhesion, migration, transmigration (Figure 1C) and route of transmigration 161 
(transcellular or paracellular) [Figure 1 near here].  162 
 163 
3.2 Validation of the 4D Imaging System using Autologous Serum  164 
To validate this in vitro system we recruited 17 active and 8 remission AAV patients, plus 16 165 
healthy donors. Clinical features and immunosuppressive treatments of AAV patients are 166 
summarised in Table 1.  We then incubated AAV patient or healthy donor leukocytes with a 167 
HUVEC-C monolayer in the presence of autologous serum. In these experiments neutrophil 168 
degranulation was significantly higher in the active AAV patient cohort compared to HCs (P = 169 
0.0002) (Figure 2A). Active AAV patient monocytes had similar rates of degranulation 170 
compared to HCs (P = 0.0910) (Figure 2B). We then compared leukocyte degranulation in 171 
patients with active disease (BVAS > 0) with those in remission (BVAS = 0).  A significantly 172 
higher neutrophil degranulation was observed in those with active disease (P = 0.0028) (Figure 173 
2C), but no difference was detected in monocyte degranulation (data not shown). Both 174 
monocytes and neutrophils from active AAV patients and HCs had a similar mean migration 175 
over 3 hours (supplementary material Table 2). Neutrophils from AAV patients had 176 
significantly higher rates of transmigration than HC neutrophils (P = 0.0096) (Figure 3A). The 177 
percentage of the monocyte population that transmigrated the endothelial cell layer 178 
demonstrated no significant difference between active AAV and HCs (P = 0.0907) (Figure 3B). 179 
Neutrophils from AAV patients showed a preference for transcellular transmigration, although 180 
this was not statistically significant (P = 0.0525) (Figure 3C). However, the AAV monocytes 181 
that did transmigrate indicated a significant preference for transcellular transmigration 182 
compared to HCs (P = 0.0008) (Figure 3D) [Table 1, and Figure 2 and 3 near here].  183 
 184 
3.3 Polyclonal ANCA IgG stimulates leukocyte degranulation but not transmigration 185 
We used protein G purified polyclonal PR3-ANCA, MPO-ANCA, or control IgG to further 186 
validate and highlight leukocyte-endothelial dynamics that may be ANCA-dependent in this 187 
system. 188 
We demonstrated that MPO-ANCA, but not PR3-ANCA, stimulated neutrophil (P < 0.001) 189 
(Figure 4A), not monocyte (Figure 4B), degranulation compared to control IgG. There was no 190 
significant difference in migration (supplementary material Table 4) or any transmigration 191 
parameters (Figure 4C/D/E/F) of neutrophils or monocytes when stimulated with either MPO-192 
ANCA, PR3-ANCA or control polyclonal IgG [Figure 4 near here]. 193 
3.4 C5aR1 Inhibition Reduces Neutrophil Degranulation 194 
We used the C5aR1 antagonist, NDT 9513727, to explore the system’s potential to study 195 
leukocyte dynamics in the presence of immunomodulatory agents. C5aR1 inhibition resulted 196 
in reduced neutrophil (P = 0.0002) (Figure 5A), but not monocyte (Figure 5B), degranulation 197 
in active AAV patients’ samples compared to control DMSO. C5aR1 inhibition was associated 198 
with a decrease in monocyte (P = 0.0440), but not neutrophil, migration compared to control 199 
DMSO (supplementary material Table 3). Transmigration of neither neutrophils or monocytes 200 
from AAV patients were affected by C5aR1 inhibition, including total population percentage 201 
that transmigrated, the route or the total distance of transmigration (supplementary material 202 
Table 3) [Figure 5 near here].  203 
 204 
  205 
4. Discussion 206 
Numerous studies have investigated the role of leukocytes in AAV, however to our knowledge 207 
this is the first in vitro 4D live-cell imaging platform that encompasses several biological 208 
readouts into one assay, particularly within the context of this disease. The development of this 209 
system required staining of neutrophil, monocytes and endothelial cells in order to image live 210 
cells with minimal impact from phototoxicity. This has allowed us to quantify spatial and 211 
temporal dynamics of monocyte and neutrophil-endothelial dynamics, demonstrating altered 212 
functions between AAV patients and the healthy population. In addition, the use of C5aR1 213 
antagonism validates the system as a useful tool for screening of therapeutic compounds 214 
through its ability to alter leukocyte dynamics.  215 
The use of autologous serum in our study highlighted an increased propensity of AAV 216 
neutrophils to degranulate significantly more than healthy donors. Of further interest was the 217 
significantly increased degranulation of neutrophils in active patients compared to those in 218 
remission. This indicates that the presumed proinflammatory profile of the serum during active 219 
disease maintains its influence in vitro. Our results extends on the body of literature that 220 
neutrophil degranulation contributes to the pathophysiology of AAV [4,19]. Our imaging 221 
system has the advantage of quantifying degranulation in a co-culture system, unlike traditional 222 
biochemical assays that cannot distinguish between cell types. To our knowledge, there is no 223 
previously published data on degranulation of neutrophils, monocytes and endothelial cells in 224 
a co-culture. Therefore, our data may not be directly comparable to neutrophils or monocytes 225 
when assayed alone.  226 
We showed that MPO-ANCA, but not PR3-ANCA, stimulated TNF-α primed neutrophil and 227 
monocyte degranulation significantly more than anti-GBM, or control IgG in neutrophils. 228 
MPO-ANCA has been shown to be a more potent stimulator of neutrophils in vitro [20] and 229 
has demonstrated greater success in development of animal models of the disease [21]. 230 
Polyclonal ANCA IgG has been used in previous studies to stimulate degranulation in 231 
neutrophils and monocytes [5,19,22] and was used as a method to validate this important 232 
dynamic in this system. The use of monoclonal ANCA would likely produce less variable 233 
results. This is because monoclonal antibodies have higher specificity for a single epitope, as 234 
opposed to polyclonal IgG, which recognises multiple epitopes [23,24]. It has been shown that 235 
ANCA IgG has different affinities [25,26] and avidities [27] and can result in altered clinical 236 
or in vitro phenotypes. This was further supported in a brief report from Popat and Robson [28] 237 
who recently suggested that polyclonal ANCA IgG does not consistently stimulate TNF-α 238 
primed neutrophils, echoing the findings from Franssen et al., [29], much to the contrary of 239 
abundantly published literature in the field.  240 
In our system, the use of a C5a receptor antagonist, showed a significant reduction in the 241 
incidences of neutrophil degranulation, supporting a role for C5a in neutrophil activation and 242 
involvement in AAV pathogenesis [30,31]. More importantly, this result validates the ability 243 
of this imaging system to demonstrate manipulation of leukocyte dynamics through potential 244 
therapeutic interventions, serving as an important tool for future studies.  245 
There is conflicting evidence on the role of ANCA on transmigration dynamics [32,33]. Our 246 
data demonstrated that active AAV neutrophils had an increased rate of transmigration 247 
compared to healthy donors in the presence of autologous serum but not with ANCA IgG. Of 248 
interest, was the significant preference for transcellular transmigration seen in active AAV 249 
monocytes. This pattern may be relevant for disease pathogenesis but needs to be replicated in 250 
other in vitro and in vivo studies to clarify. Previous studies suggested the contribution of 251 
dominant expression of adhesion molecules such as ICAM-1 and PECAM-1 in driving 252 
transcellular transmigration [34]. There was no difference in leukocyte transmigration 253 
dynamics in our system in the presence of C5aR1 inhibitor, despite C5a being known as a 254 
potent chemoattractant to both neutrophils and monocytes [35]. Often leukocyte transmigration 255 
is measured using a Transwell® insert [36]. In our system, we quantify transmigration through 256 
visualisation of the XZ- or YZ-planes. This allows multiple metrics of transmigration to be 257 
quantified such as total population transmigrating, depth of leukocyte movement, as well as 258 
the route of transmigration i.e. paracellular or transcellular. A further improvement in 259 
transmigration rates may have occurred if HUVEC were primed with TNF-α prior to addition 260 
of autologous sera, as demonstrated during our polyclonal ANCA experiments. Furthermore, 261 
this system may be enhanced by the addition of flow or with an upper/lower chamber to more 262 
easily facilitate leukocyte movement and to allow the application of chemotactic agents, such 263 
as N-formyl-L-methionyl-L-leucyl-phenylalanine (fMLP). 264 
Much of the literature in AAV focuses on the influence of purified ANCA on neutrophil 265 
dynamics but our data intimates that serum factors also play a crucial role in transmigration 266 
and degranulation independent of ANCA. This is similar to the findings of Kraaij et al., [37] 267 
who reported that depletion of IgG from active AAV patient serum retained the ability to 268 
produce excessive NET formation, but contrary to our finding on degranulation, this was not 269 
dependent on C5aR. Our data demonstrated a high degree of heterogeneity across all 270 
populations. This may represent altered pro-inflammatory profiles due to the heterogeneous 271 
nature of the disease and the variation in clinical scores of patients recruited. An increased 272 
sample size, in addition to longitudinal data, may improve this. Furthermore, given the 273 
endothelial necrosis seen in AAV pathogenesis in vivo, a limitation of this system is that it 274 
highlights early events, but not the long-term effects, of serum or ANCA on endothelial health.  275 
We have developed a 4-dimensional live-cell imaging system that can investigate key functions 276 
of leukocytes in the context of health and disease and can be used as a tool to investigate 277 
potential therapeutic targets. Furthermore, the system has the capacity to examine many other 278 
relevant pathological mechanisms including neutrophil extracellular trap (NET)-osis, micro-279 
particle- and platelet-endothelial interactions. It is to be determined whether the multi-metric 280 
co-culture dynamics of this 4D live-cell imaging system outweigh the use of multiple in vitro 281 
biochemical measurements. During characterisation of this system, our preliminary data 282 
demonstrates that neutrophils and monocytes likely contribute to the AAV pathophysiology 283 
through dominant mechanisms and that these functions in AAV are altered compared to healthy 284 
donor leukocytes. 285 
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Table 1 - Patient Characteristics (autologous serum experiments) 414 
Figure 1: 4-Dimensional Live Cell Imaging Model of ANCA-associated Vasculitis. A) 415 
Video 1 still image of 4D in vitro model of AAV. B) Video 2 still image depicting independent 416 
cell populations during analysis. C) XZ plane micrograph showing transmigration through 417 
endothelial cell layer. D) Video 3 still images of monocyte degranulation from 60-160 min 418 
showing sequential release of monocyte-derived particles subsequently seen around body of 419 
cell (scale bar = 25 µm). Monocytes (DiD - red); neutrophils (DiO - green); HUVEC (CellTrace 420 
Violet - blue). 4D – 4-dimensional; ANCA - anti-neutrophil cytoplasmic antibodies; AAV – 421 
ANCA-associated vasculitis; HUVEC – human umbilical vein endothelial cell 422 
Figure 2: Leukocyte Degranulation. Data represents percentage of population exhibiting 423 
degranulation during 3-hour imaging assay with autologous serum. Degranulation of active 424 
AAV versus healthy donors in A) neutrophils (n = 16; 12) (P = 0.0002) and B) monocytes (n 425 
= 16; 13) (P = 0.0910). C) Neutrophils from active patients (n = 16) versus remission patients 426 
(n = 7) (P = 0.0028). Data shown is mean ± SEM. Data tested for Gaussian distribution. 427 
Unpaired t-test (A/B/C); ** P< 0.01; *** P<0.001.  428 
Figure 3: Leukocyte Transmigration. Data represents percentage of population that 429 
transmigrate HUVEC during 3 hour imaging assay with autologous serum. A) Neutrophil 430 
transmigration (n = 16; 6) (P = 0.0096) B) monocyte transmigration (n = 16; 7) (P = 0.0907) 431 
C) Neutrophil transcellular (n = 16; 6)(P = 0.0525) D) monocyte transcellular (n = 16; 7)(P = 432 
0.008). Data shown is mean ± SEM. Data tested for Gaussian distribution. Unpaired t-test; ** 433 
P< 0.01, *** P<0.001. 434 
Figure 4: Polyclonal ANCA IgG. Data represents the percentage population of healthy donor 435 
TNF-α primed leukocytes exhibiting measured functions following stimulation with polyclonal 436 
PR3-ANCA (n = 9), MPO-ANCA (n = 11), or control IgG (n = 8). A) Neutrophil degranulation 437 
(***P < 0.001) B) Monocyte degranulation C) Neutrophil transmigration D) Monocyte 438 
transmigration E) Neutrophil transcellular route F) Monocyte transcellular route. Data shown 439 
is mean ± SEM.     Anti-GBM control IgG. Data tested for Gaussian distribution. One-way 440 
ANOVA with Bonferroni multiple comparison test. 441 
Figure 5: C5aR1 Degranulation. Inhibition of C5aR1 versus control DMSO (n = 6) A) 442 
Neutrophils (P = 0.0002). B) Monocytes (P = 0.9560). Data shown is mean ± SEM. Paired t-443 
test *** P<0.001. 444 
Table 1 Patient Characteristics (autologous serum experiments) 
 
Variables    
 Active Patient (n = 17) Remission Patient (n = 8) Healthy (n = 16) 
Age, median (range), years 59 (40-77) 62 (50-72) 43 (27-60) 
Sex, male 10 (59%) 7 (88%) 8 (44%) 






































Disease duration, median 
(range), years  
1.58 (0.01 – 8.5) 6.5 (1-29) n/a 
BVAS Score, median (range) 7 (2-26) 0  n/a 













Serum Creatinine (μM/L) 99 (57-582) 80 (69-122) n/a 
Raised CRP > 4 mg/L 9 (53%) 4 (50%) n/a 
























Abbreviations;  AAV – ANCA-associated Vasculitis; ANCA – Anti-neutrophil Cytoplasmic Antibodies;  BVAS – 
Birmingham Vasculitis Score;  CRP – C-reactive Protein; EGPA – Eosinophilic Granulomatosis with Polyangiitis;  
ENT - Ear, Nose, Throat;  eGFR - estimated Glomerular Filtration Rate; GPA – Granulomatosis with Polyangiitis; 
MPA – Microscopic Polyangiitis; MPO – Myeloperoxidase; PR3 - Proteinase 3 
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Figure 1 - 4-Dimensional Live Cell Imaging Model of ANCA-associated Vasculitis. A) Video 1 still image of 4D in vitro model of AAV. B) Video 2 still image depicting
independent cell populations during analysis. C) XZ plane micrograph showing transmigration through endothelial cell layer. D) Video 3 still images of monocyte
degranulation from 60-160 min showing sequential release of monocyte-derived particles subsequently seen around body of cell (scale bar = 25 µm).
Monocytes (DiD - red); neutrophils (DiO - green); HUVEC (CellTrace Violet - blue). 4D – 4-dimensional; ANCA - anti-neutrophil cytoplasmic antibodies; AAV –
ANCA-associated vasculitis; HUVEC – human umbilical vein endothelial cell
Figure 2: Leukocyte Degranulation. Data represents percentage of population exhibiting degranulation during 3 hour 
imaging assay with autologous serum. Degranulation of active AAV versus healthy donors in A) neutrophils (n = 16; 12) 
(P = 0.0002) and B) monocytes (n = 16; 13) (P = 0.0910). C) Neutrophils from active patients (n = 16) versus remission 
patients (n = 7) (P = 0.0028). Data shown is mean ± SEM. Data tested for Gaussian distribution. Unpaired t-test (A/B/C) 
; ** P< 0.01; *** P<0.001. 
Figure 3: Leukocyte Transmigration. Data represents percentage of population that transmigrate 
HUVEC during 3 hour imaging assay with autologous serum. A) Neutrophil transmigration (n = 16; 6) (P 
= 0.0096) B) monocyte transmigration (n = 16; 7) (P = 0.0907) C) Neutrophil transcellular (n = 16; 6)(P = 
0.0525) D) monocyte transcellular (n = 16; 7)(P = 0.008). Data shown is mean ± SEM. Data tested for 
Gaussian distribution. Unpaired t-test; ** P< 0.01, *** P<0.001
Figure 4: Polyclonal ANCA IgG. Data represents the percentage population of healthy donor TNF-α primed leukocytes exhibiting measured functions 
following stimulation with polyclonal PR3-ANCA (n = 9), MPO-ANCA (n = 11), or control IgG (n = 8). A) Neutrophil degranulation (***P < 0.001) B) 
Monocyte degranulation C) Neutrophil transmigration D) Monocyte transmigration E) Neutrophil transcellular route F) Monocyte transcellular route. 
Data shown is mean ± SEM.     Anti-GBM control IgG. Data tested for Gaussian distribution. One-way ANOVA with Bonferroni multiple comparison 
test.
Figure 5: C5aR1 Degranulation. Inhibition of C5aR1 versus control DMSO (n = 6) A) Neutrophils (P = 0.0002). B) Monocytes 
(P = 0.9560). Data shown is mean ± SEM. Paired t-test *** P<0.001
